The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the public warrants (the “Warrants”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) — ticker symbol DNA.WS — each Warrant exercisable for one-fortieth (1/40) of one share of the Company’s Class A common stock, par value $0.0001 per share (the “Class A common stock”), at an exercise price of $11.50 per Warrant, from the NYSE. Trading in the Company’s Warrants will be suspended immediately. Trading in the Company’s Class A common stock — ticker symbol DNA — will continue on the NYSE.

NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low selling price” levels, pursuant to Section 802.01D of the NYSE Listed Company Manual.

The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s Warrants upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904904146/en/